(Q33931265)

30 July 2017

title

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy (English)

1 reference

30 July 2017

main subject

anti-retroviral agent

0 references

Steven G Deeks

1 reference

30 July 2017

Christos J Petropoulos

object named as

Christos Petropoulos

1 reference

30 July 2017

Hiroyu Hatano

1 reference

30 July 2017

Harry Lampiris

1 reference

30 July 2017

Signe Fransen

1 reference

30 July 2017

Soumi Gupta

1 reference

30 July 2017

Wei Huang

1 reference

30 July 2017

Rebecca Hoh

1 reference

30 July 2017

Jeffrey N Martin

1 reference

30 July 2017

Jacob Lalezari

1 reference

30 July 2017

David Bangsberg

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Journal of Acquired Immune Deficiency Syndromes

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

389-393

1 reference

Maraviroc for previously treated patients with R5 HIV-1 infection

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Raltegravir with optimized background therapy for resistant HIV-1 infection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890029

Update of the drug resistance mutations in HIV-1: Spring 2008

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20300008

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAI.0B013E3181C42EA4

1 reference

30 July 2017

1 reference

30 July 2017

1 reference